Evaluation of the Benefit of Lidocaine on the Prevention of the Risk of Post Endoscopic Retrograde Cholangio-pancreatography Pancreatitis. (PEPLID)

The goal of this study is, in a population of patients undergoing ERCP surgery, treated preventively with NSAIDs and divided into two groups according to the absence (group 1) or presence (group 2) of intravenous lidocaine in the general anesthesia protocol.

The main objective of this study is to compare the incidence of post-ERCP pancreatitis between the two groups.

type of study: clinical trial participant population/health conditions: Patients with ERCP surgery

Study Overview

• Status: Recruiting
• Conditions: ERCP Surgery
• Intervention / Treatment: Drug: Intravenous lidocaine administration

Detailed Description

This is a single-center, prospective, randomized, single-blind study of two parallel groups of patients undergoing ERCP surgery

• Group 1 (n=900): General anesthesia without IV lidocaine administration
• Group 2 (n=900): General anesthesia with IV lidocaine administration

Randomization Patients who have given written informed consent and received confirmation of eligibility will be randomized into the study according to a randomization list. According to the randomization, patients will be divided into two equal groups of 900 patients (anesthesia with and without lidocaine). The randomization list will be established by a centralized computer procedure.

PAP prevention protocols Treatment with indomethacin (100mg intrarectally), which is the reference preventive treatment, will be administered systematically in both groups just before anesthesia (or during anesthesia if ERCP is preceded by an echo-endoscopy). The endoscopic techniques to prevent PAP (pancreatic prosthesis, double guide wire technique, infundibulotomy, needle pre-cutting ...) will be used by the operator according to his procedural habits and will be reported in the CRF.

Anesthesia protocol

All patients will be operated under general anesthesia with orotracheal intubation without premedication with the same anesthesia protocol:

At induction: a hypnotic (propofol or hypnomidate) combined with a morphine (sufentanil or remifentanyl) and low doses of Ketamine and midazolam, with or without curarization.

In maintenance phase sevoflurane. Blood pressure will be maintained by administration of ephedrine, neosynephrine or baby noradrenaline. The patient's hydration will be ensured by an infusion of Ringer Lactate (20ml/Kg).

In the postoperative period, analgesic treatment will be systematically administered with, according to the needs, palliative analgesics 1 or 2 or morphine titration.

Lidocaine administration protocol Patients randomized in group 2 will receive during anesthesia a treatment with 1% non-adrenalized Lidocaine.

An initial bolus (1.5mg/kg) will be administered at induction of anesthesia (or upon ERCP decision if echo-endoscopy is in progress).

Then IVSE of lidocaine at 2mg/Kg/hr will be started for one hour (to be continued in the ICU if needed).

• Study Type: Interventional
• Enrollment (Estimated): 1800
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Gianfranco DONATELLI, MD; Phone Number: 33 01 44 16 52 00; Email: donatelligianfranco@gmail.com

Study Locations

• France
  • Paris, France, 75013
    • Recruiting
    • Hopital Prive des Peupliers
    • Contact: Gianfranco DONATELLI, MD; Phone Number: 33 01 44 16 52 00; Email: donatelligianfranco@gmail.com
    • Principal Investigator: Gianfranco Gianfranco, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patient over 18 years of age
• Patient who has read and signed the consent form for participation in the study
• Patient candidate for ERCP with virgin papilla

Exclusion Criteria:

• Patient with sphincterotomized papilla
• Patient under court protection, guardianship or curatorship
• Pregnant woman or woman of childbearing age without highly effective contraception for the duration of the study (surgically sterile, intrauterine device (> 14 days), hormonal contraception (same dose and formulation for at least 6 months), sexual abstinence. Women after menarche and until they become postmenopausal, unless they are permanently infertile or have undergone surgical sterilization, are considered to be of childbearing age, i.e. fertile. A postmenopausal condition is defined as the absence of menstruation for 12 months without any other medical cause
• Patient not affiliated with the French social security system
• Patient participating in another clinical research protocol
• Impossibility to give the subject informed information and/or written informed consent: dementia, psychosis, disorders of consciousness, non-French speaking patient
• Contraindication to the use of NSAIDs
• Contraindication to anesthesia or to the administration of any of the products used in anesthesia protocols (including lidocaine)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
No Intervention: General anesthesia without intravenous lidocaine administration
Experimental: General anesthesia with intravenous lidocaine administration	Drug: Intravenous lidocaine administration; General anesthesia with intravenous lidocaine administration

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Plasma lipase level	A plasma lipase level greater than or equal to 3N, considered to be indicative of a PAP, is the primary endpoint of the study	Hour 24

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Abdominal pain intensity	Assessment of abdominal pain on a simple numerical scale	Hour 24
Pancreatic ultrasound or CT scan data	Pancreatic ultrasound or CT scan data if available	Hour 24
Severity of pancreatitis	Severity of pancreatitis according to the ATLANTA 2012 criteria	Hour 24

Collaborators and Investigators

• Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche

Study record dates

Study Major Dates

• Study Start (Actual): January 18, 2024
• Primary Completion (Estimated): January 18, 2026
• Study Completion (Estimated): February 28, 2026

Study Registration Dates

• First Submitted: December 19, 2022
• First Submitted That Met QC Criteria: December 19, 2022
• First Posted (Actual): December 29, 2022

Study Record Updates

• Last Update Posted (Estimated): December 3, 2025
• Last Update Submitted That Met QC Criteria: November 25, 2025
• Last Verified: November 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Pancreatic Diseases; Pancreatitis; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Arrhythmia Agents; Central Nervous System Depressants; Peripheral Nervous System Agents; Sensory System Agents; Anesthetics; Membrane Transport Modulators; Anesthetics, Local; Voltage-Gated Sodium Channel Blockers; Sodium Channel Blockers; Lidocaine
• Other Study ID Numbers: 2022-A01658-35

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No